Thrombolytic Therapy Dynamics in Ischemic Stroke

Thrombolytic therapy for acute ischaemic stroke aims to dissolve obstructive thrombi in cerebral arteries and restore perfusion. Central to this process is administration of tissue plasminogen activator (tPA), which catalyses fibrin degradation within the clot. The interplay between drug kinetics, clot microstructure and haemodynamic forces determines the rate of recanalisation and the risk of intracranial haemorrhage. Advances in computational modelling and experimental platforms have yielded mechanistic insights into how dosing regimens, infusion protocols and clot heterogeneity influence the spatial and temporal evolution of lysis. Integration of pharmacokinetic–pharmacodynamic models with three-dimensional vascular geometries has enabled patient-specific predictions of treatment efficacy. Emerging in-silico trials and mesoscale simulations are now probing optimal delivery strategies, balancing rapid reperfusion against bleeding complications. This growing body of work provides a quantitative framework to guide clinical decision-making and device development in stroke thrombolysis.

Research from Nature Portfolio

Recent studies have developed simplified computational frameworks to characterise the dynamics of thrombolytic therapy under physiologically relevant flow conditions. One work introduced a mesoscale three-dimensional model of fibrinolysis in which a thrombus is treated as a porous medium subject to a second-order reaction cascade. This approach reproduced non-linear lysis front propagation and offered a route to extract key physiological parameters governing treatment efficacy and failure. Another foundational effort employed patient-specific computational simulations coupling three-dimensional vessel geometries with compartmental pharmacokinetic models of tissue plasminogen activator infusion. The model quantified how variations in clot microstructure and tPA dosing alter the rate of recanalisation and the risk of intracranial haemorrhage, highlighting the trade-off between rapid clot dissolution and safety.

Thrombolytic Therapy Dynamics in Ischemic Stroke publication trend

The graph below shows the total number of articles in thrombolytic therapy dynamics in ischemic stroke across all publications each year (not limited to Nature Index journals).

Technical terms

Tissue Plasminogen Activator (tPA): A serine protease enzyme used therapeutically to catalyse the conversion of plasminogen to plasmin, thereby promoting fibrinolysis.

Fibrinolysis: The biochemical process through which fibrin fibres within a blood clot are enzymatically degraded to restore vessel patency.

Lysis Front: The advancing boundary at which active fibrin degradation occurs within a clot during thrombolytic therapy.

Porous Medium Model: A mathematical representation treating a blood clot as a permeable structure through which drug and fluid transport follow reaction-diffusion-convection laws.

Recanalisation: The restoration of blood flow through a previously occluded artery following clot dissolution or removal.

In-silico Trial: A computer-based simulation of a clinical trial that uses virtual patient cohorts to predict treatment outcomes and optimise trial design.

References

1. A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions. Scientific Reports (2023).
2. In-Silico Trials for Treatment of Acute Ischemic Stroke. Frontiers in Neurology (2020).
3. Computational Simulations of Thrombolytic Therapy in Acute Ischaemic Stroke. Scientific Reports (2018).
4. Mathematical Modelling of Intravenous Thrombolysis in Acute Ischaemic stroke: Effects of Dose Regimens on Levels of Fibrinolytic Proteins and Clot Lysis Time. Pharmaceutics (2019).
5. Towards a multi-physics modelling framework for thrombolysis under the influence of blood flow. Journal of The Royal Society Interface (2015).
6. In silico trials for treatment of acute ischemic stroke: Design and implementation. Computers in Biology and Medicine (2021).